ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1657

Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis

Marie Binvignat1, Maria Marco-Salvador1, Johanna Dubois1, Paul Stys1, Alice Courties2, Fabien Pitoiset1, Alexandra Roux3, Michele Barbier4, Roberta Lorenzon2, Signe Hassler3, Claire Ribet1, helene Vantomme1, Leslie Adda1, Vanessa Mhanna1, Nicolas Coatnoan2, Gwladys Fourcade1, Vimala Didelot1, PIerre Barennes1, Lise Minssen2, Caroline Aheng1, Sanchita Bhattacharya5, Yannick Marie6, Atul J. butte5, Adrien Six1, Nicolas Tchitcheck1, Michelle Rosenzwajg1, Francis Berenbaum1, David Klatzmann1, Encarnita Mariotti-Ferrandiz1 and Jérémie Sellam7, 1Sorbonne University, Paris, France, 2AP-HP, Paris, France, 3Sorbonne University, Paris, 4AP-HP, Paris, 5UCSF, San Francisco, 6ICM, Paris, France, 7Saint-Antoine Hospital - AP-HP, Paris, Ile-de-France, France

Meeting: ACR Convergence 2024

Keywords: Bioinformatics, immunology, Osteoarthritis, pain, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Osteoarthritis & Joint Biology – Basic Science

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Pain is the main osteoarthritis (OA) symptom and remains poorly understood. While significant attention has been given to the potential role of innate immunity, few studies have explored the role of adaptive immunity. Our aim was to identify a comprehensive systemic immunological signature of OA-related pain, with a particular emphasis on the role of Tregs and Teffs.

Methods: We enrolled 46 patients with radiographic knee OA as part of the TRANSIMMUNOM clinical trial (NCT02466217). Patients with total knee replacement, Kellgren-Lawrence score of 4, or associated autoimmune disease were excluded. Clinical data were collected for each patient, including WOMAC pain and DN4 scores. Blood deep immunophenotyping was performed using 12 different flow cytometry panels (Duraclone technology, Beckman Coulter). Sixty-two serum cytokines were quantified using the Luminex Multiplex Assay xMAP® Technology. TCR analysis and RNA sequencing were performed on sorted CD4+CD25+CD127- Treg cells and Teffs with a purity > 80%. TCR and RNA sequencing were performed on libraries prepared with SMART-Seq® v4 Ultra® Low Input RNA Kit on high-quality RNA. Differential gene expression analysis using DESEq2 and functional analysis using GO databases were applied.

Results:  The cohort consisted of 65.2% women with a mean age of 64.8 years and BMI of 29.1 kg/m2. The mean WOMAC pain score was 44.2 (SD=12.7), with no significant difference between patients with low and high pain intensity (WOMAC pain ≥ 40/100) in terms of age, BMI, sex, and radiographic severity. Unsupervised analysis of 269 immune cell based on a deep immunophenotyping identified 19 and 22 cell populations that correlated with WOMAC pain and DN4, respectively (p< 0.05 |r|≥0.2). Among these, four populations related to Treg activation and functionality (FoxP3+CTLA4+, CD4+CD57+, Treg CD95+, and CD4 Treg CD45RA+) were negatively correlated with the WOMAC pain score. Cytokine analysis revealed that soluble factors associated with Treg expansion and activation (sIL2-RA, sTNFR1, sTNFR2, IL-22) were also associated with WOMAC pain score (figure 1). Clonal distribution of Tregs and Teffs cells using T-cell receptor repertoire (TCR) sequencing showed a positive correlation (p< 0.001, r= 0.6) between CD4+ Teff TCR diversity and WOMAC score. Differential gene expression analysis of Tregs between patients with low and high WOMAC pain scores identified 320 upregulated genes, including inflammasome-related genes such as IL1RL1, IL31RA, IFITM3, NLRP3, INFG, and TNFRSF14, and 123 downregulated genes (|log2(FC)|≥log2(1.6), p< 0.01). There was also an overrepresentation and enrichment of GO pathways related to innate immune regulation, cytokine production, IL-8 activation, and IFN-gamma production (p< 0.01) (figure 2).

Conclusion:  This study reports an extensive blood immune profiling of knee OA pain, emphasizing systemic dysregulation of Tregs with a potential pro-inflammatory state and loss of functionality. These findings underscore the involvement of the adaptive immune system in OA pain, extending beyond conventional low-grade inflammation paradigms and offering novel pathophysiological insights.

Supporting image 1

Figure 1. A. Graphical Abstract. B Non paramettric Spearman Correlation analysis of cell populationin deep immune-phenotyping WOMAC pain, DN4 and HADS. Expression heatmap between low and high sympatomic knee OA patients. C. WOMAC pain and DN4 cytokines correlation network

Supporting image 2

Figure 2. A. Differential gene expressionin sorted Tregs between patients with low and high pain intensity B GO over-representation analysis in Tregs associated with OA pain . C.Top gene contribution to the main functional pathways overrepresented


Disclosures: M. Binvignat: None; M. Marco-Salvador: None; J. Dubois: None; P. Stys: None; A. Courties: None; F. Pitoiset: None; A. Roux: None; M. Barbier: None; R. Lorenzon: None; S. Hassler: None; C. Ribet: None; h. Vantomme: None; L. Adda: None; V. Mhanna: None; N. Coatnoan: None; G. Fourcade: None; V. Didelot: None; P. Barennes: None; L. Minssen: None; C. Aheng: None; S. Bhattacharya: None; Y. Marie: None; A. butte: NuMedii, 8; A. Six: None; N. Tchitcheck: None; M. Rosenzwajg: None; F. Berenbaum: 4Moving Biotech, 8, 10, 11, 4P Pharma, 2, 11, AstraZeneca, 2, GlaxoSmithKlein(GSK), 2, Grunenthal, 2, Nordic Pharma, 6, Novartis, 2; D. Klatzmann: None; E. Mariotti-Ferrandiz: None; J. Sellam: AbbVie/Abbott, 7, Bristol-Myers Squibb(BMS), 7, Fresenus kabi, 7, Galapagos, 7, Grunenthal, 7, MSD, 7, Nordic Pharma, 7, Novartis, 7, Pfizer, 7.

To cite this abstract in AMA style:

Binvignat M, Marco-Salvador M, Dubois J, Stys P, Courties A, Pitoiset F, Roux A, Barbier M, Lorenzon R, Hassler S, Ribet C, Vantomme h, Adda L, Mhanna V, Coatnoan N, Fourcade G, Didelot V, Barennes P, Minssen L, Aheng C, Bhattacharya S, Marie Y, butte A, Six A, Tchitcheck N, Rosenzwajg M, Berenbaum F, Klatzmann D, Mariotti-Ferrandiz E, Sellam J. Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/immunological-profiling-of-pain-in-knee-osteoarthritis-treg-cells-as-potential-new-key-players-in-symptomatic-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunological-profiling-of-pain-in-knee-osteoarthritis-treg-cells-as-potential-new-key-players-in-symptomatic-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology